1、Accelerate the R&D Process of Metabolic Disease Drugs – A Precise and Predictable Solution for In Vivo Efficacy Evaluation

2、Service Overview

The R&D of new drugs for metabolic diseases (e.g., obesity, diabetes, non-alcoholic steatohepatitis) faces industry pain points such as low clinical conversion rate and insufficient model predictability. Traditional animal models are unable to accurately simulate human pathological characteristics, leading to a disconnect between efficacy data and clinical outcomes. Jennio provides highly humanized animal models of metabolic diseases and a multi-dimensional evaluation system. By accurately simulating disease progression (e.g., insulin resistance, liver fibrosis), we shorten the R&D cycle and significantly reduce the risk of clinical failure.

3、Our Services

• ：Classified by disease type and evaluation dimension:
• （1）（Obesity）
  • Model: High-fat diet (HFD)-induced obese mouse model (DIO), modeling in 16 weeks.
  • Detection indicators: Dynamic body weight monitoring, epididymal fat weight, fasting blood glucose, oral glucose tolerance test (OGTT), in vivo microCT quantitative analysis of subcutaneous/visceral fat.
  • Technical highlights: Combined with microCT 3D imaging for accurate quantification of fat distribution.
• （2）（Type 2 Diabetes）
  • Models:
    • ① Chemically induced: High-fat diet combined with streptozotocin (STZ) induction ;
    • ② Spontaneous: db/db mice (leptin receptor mutation, highly simulating human disease progression).
  • Detection indicators: Blood glucose, insulin level, glycated hemoglobin (HbA1c), pancreatic tissue pathology (HE staining), glucagon, C-peptide level.
• （3）Non-Alcoholic Steatohepatitis (NASH)
  • Model: C57BL/6 mice induced by high-fat diet with or without carbon tetrachloride (CCl₄) for 16 weeks, with typical pathological features including hepatic steatosis, inflammatory infiltration, tissue necrosis, and small-area tissue fibrosis.
  • Detection indicators: Serum ALT/AST, hepatic TG/TC content, tissue HE staining (quantification of fat vacuoles), Masson staining (fibrotic collagen deposition), fibrosis markers (α-SMA, collagen deposition)
• （4）（Liver Fibrosis）
  • Model: Liver fibrosis in rats/mice induced by intraperitoneal injection of CCl₄ for 8 weeks, stably reproducing fibrotic pathology.
  • Detection indicators: Liver function (AST/ALT), Masson staining of liver tissue (fibrotic collagen deposition scoring), HE staining (evaluation of inflammatory infiltration and tissue necrosis).

4、Technical Platforms and Advantages

• （1）Core Technical Platforms
  • In Vivo Imaging Platform: MicroCT non-destructive scanning for fat distribution, supporting quantitative analysis of visceral/subcutaneous fat volume ratio.
  • Pathological Analysis Platform: HE/Masson/Oil Red O staining for accurate assessment of steatosis, inflammation and fibrosis .
  • Molecular Detection Platform: qPCR (inflammatory factors TNF-α, IL-6), ELISA (insulin, adiponectin), Western Blot (signaling pathway proteins).
• （2）Differentiated Advantages
  • High clinical relevance: The db/db mouse model spontaneously exhibits typical characteristics of human type 2 diabetes (obesity, hyperglycemia, insulin resistance).
  • Multi-model linkage: Supporting the simulation of the full-chain disease progression from obesity → diabetes → NASH → liver fibrosis.
  • One-stop detection: Integrating multi-dimensional data of physiological indicators (body weight, blood glucose), imaging (fat distribution), histopathology and molecular mechanisms.

5、Service Process

• Demand Communication (response within 1 working day):
  • Customization of model solutions (e.g., selection of db/db mouse or HFD+STZ model).
• Experiment Execution:
  • ① Model construction (e.g., 16-week HFD modeling);
  • ② Drug administration (oral/injection);
  • ③ Real-time progress sharing (weekly reports + preview of key node data).
• Data Delivery:
  • ① GLP-aligned standard reports (raw data + statistical analysis charts);
  • ② Typical deliverables: Body weight curves, microCT 3D imaging of fat, histopathological section images, heat maps of biochemical indicators.

6、Quality Control and Compliance

• Execution Standards:Adhering to GLP-aligned specifications throughout the process (experimental design, data recording, report generation).
  • Quality Control Measures:Double independent data review, regular calibration of instruments (e.g., microCT accuracy verification).
• Data Traceability:Electronic laboratory notebook system (compliant with 21 CFR Part 11 requirements).

7、Case Studies

Case 1: In Vivo Evaluation of Anti-Obesity Drugs

• Model: HFD-induced obesity in C57BL/6 mice (16 weeks).
• Intervention: Oral treatment with candidate drug X for 4 weeks.
• Results: Significant reduction in body weight (VS model group, p<0.01), decrease in epididymal fat volume (VS model group, p<0.01), and significant improvement in glucose tolerance.
• Data support: Attached body weight curves and OGTT curves.

Case 2: Efficacy Verification of NASH Drugs

• Model: NASH in C57BL/6 mice induced by high-fat diet combined with CCl₄ (16 weeks).
• Intervention: Treatment with drug Y for 8 weeks.
• Results: 50% reduction in hepatic steatosis score, decreased inflammatory infiltration, and 40% reduction in serum ALT.
• Data support: Liver HE staining comparison images, serum ALT level statistics.

8、Cooperation Advantages

•  Precise model matching: Flexible selection of models according to drug mechanisms (e.g., db/db mice for the evaluation of insulin sensitizers).
•  Efficient delivery: The cycle of model construction + efficacy testing is 30% faster than the industry average (completion of standard protocols within 16 weeks).
•  End-to-end support: From model establishment and efficacy testing to preliminary mechanism exploration (e.g., WB verification of target proteins).

9、FAQ

Q: Do you support non-human primate metabolic disease models?

A: We currently focus on rodent models (mice, rats); non-human primate models require customized development.

Q: What is the data delivery cycle?

A: Basic efficacy data (body weight, blood glucose, etc.) will be delivered within 10 working days after the experiment; histopathological detection will take an additional 5 working days.

10、Laboratory Highlights

• SPF-grade Animal Facility: 5,000 cage capacity with individual ventilation cage (IVC) system.
• In Vivo Imaging Platform: High-resolution microCT (fat quantitative scanning).
• Automated Detection Platform: High-throughput biochemical analyzer (serum ALT/AST detection, daily processing capacity of over 200 samples).

View More

11、Contact Us

• Tel: +86 18802035152
• Email: 3691125803@qq.com
• Resource Download:

• Obtain a customized solution for free
• Download the Metabolic Disease Model Manual

JennioBio—Empowering the development of new drugs for metabolic diseases through precision modeling, accelerating your preclinical success.